JNJ-26489112 explained
| Iupac Name: | (S)-N-[(6-Chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide |
| Cas Number: | 871824-55-4 |
| Pubchem: | 11616111 |
| Chemspiderid: | 9790860 |
| Unii: | G1TI012DLT |
| C: | 9 |
| H: | 11 |
| Cl: | 1 |
| N: | 2 |
| O: | 4 |
| S: | 1 |
| Smiles: | NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2 |
| Stdinchi: | 1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1 |
| Stdinchikey: | KXSAIQPPGSSNKX-ZETCQYMHSA-N |
JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy.[1] [2] JNJ-26489112 was designed as a successor to topiramate.[3] It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.[3]
JNJ-26489112 was studied as a treatment for major depressive disorder. This clinical trial was terminated in 2013 due to a "sponsor portfolio decision", and no new development of JNJ-26489112 has been reported.
Its mechanism of action is unknown.[4]
See also
Further reading
- Toxicological study of JNJ-26489112: Eichenbaum G, Zhou J, Kelley MF, Roosen W, Costa-Giomi P, Louden C, Di Prospero NA, Pandina G, Singh JB, Ford L, Moyer JA, Nork TM, Ver Hoeve JN, Aguirre GD . 6 . Implications of retinal effects observed in chronic toxicity studies on the clinical development of a CNS-active drug candidate . Regulatory Toxicology and Pharmacology . 69 . 2 . 187–200 . July 2014 . 24680767 . 10.1016/j.yrtph.2014.03.005 .
Notes and References
- Trenité DK, Diprospero NA, Moyer JA, Gambale J, Pandina G, Ford L, Girgis S, Xi L, Nye J . Clinical Therapeutics . 35 . 8 . e70 . August 2013 . Evaluation of JNJ-26489112, a Novel Antiepileptic Drug: A Placebo-Controlled, Exploratory Study . 10.1016/j.clinthera.2013.07.204. free .
- Di Prospero NA, Gambale JJ, Pandina G, Ford L, Girgis S, Moyer JA, Xi L, Nye JS, Kasteleijn-Nolst Trenité D . 25545178 . 6 . Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study . Epilepsy Research . 108 . 4 . 709–16 . May 2014 . 24560845 . 10.1016/j.eplepsyres.2014.01.018 .
- McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, Klein BD, Wilcox KS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Reitz AB, Maryanoff BE . 6 . Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112) . Journal of Medicinal Chemistry . 56 . 22 . 9019–30 . November 2013 . 24205976 . 4004761 . 10.1021/jm400894u .
- Zaccara G, Schmidt D . Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development . Pharmacological Research . 104 . 38–48 . February 2016 . 26689774 . 10.1016/j.phrs.2015.12.011 .
